The Mounjaro dose chart: what each step means for your treatment

What are the six doses on the Mounjaro chart, and what does each one do?

The licensed Mounjaro doses chart runs: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg. Treatment always begins at 2.5 mg for the first four weeks. This isn't a therapeutic level in the weight-loss sense; it exists so your body can adapt to tirzepatide's mechanism (slowing gastric emptying, reducing appetite signals, and acting on both GIP and GLP-1 receptors) before the dose climbs. Many people notice little change in appetite at 2.5 mg, and that's entirely normal. The step from 2.5 mg to 5 mg, taken at week five, is often when appetite suppression becomes more noticeable.

From 5 mg onwards, each four-week step increases the dose by 2.5 mg. The final maintenance level for many people is 15 mg, though some find an earlier rung (10 mg or 12.5 mg) is their highest tolerated dose. A question our prescribers hear most weeks is whether they can skip a step to speed up results; the answer is no, and for good reason. Rushing the schedule raises the risk of side effects such as nausea, vomiting and diarrhoea, which are most pronounced when the dose increases too quickly. The BNF's tirzepatide monograph confirms the stepped schedule as standard practice for licensed UK prescribing.

For a closer look at what the individual steps mean day to day, the detailed Mounjaro dosage guide walks through each stage with practical notes. The six-step structure reflects clinical trial design: SURMOUNT-1 used the same titration to reach 15 mg, and it's the schedule that produced the trial's headline results.

When does a prescriber decide to move you up, or hold you back?

The chart sets the ceiling, not the timetable. Your prescriber decides whether to advance your dose at each four-week review based on how you're tolerating the current level, whether side effects have settled, and how your weight loss is progressing. If nausea or gastrointestinal discomfort is still significant at week four, staying at the current dose for another four weeks is a legitimate clinical decision, not a setback.

Holding a dose is common and doesn't indicate that treatment isn't working. Some people spend eight or twelve weeks at 5 mg before moving on, and their eventual outcomes are comparable to those who titrated faster. What the chart cannot tell you is how your own body will respond, that picture only emerges through the prescribing relationship. At nume, no dose increase is dispatched without clinical re-review; you don't simply renew and escalate automatically. The Mounjaro golden dose resource explores the concept of finding the optimal personal maintenance level, rather than always pushing to 15 mg.

It's also worth knowing that the prescriber may recommend staying at a dose if you are approaching a target weight, or if the current level is delivering steady progress without troublesome side effects. The chart is a tool, not a conveyor belt. For information on how costs vary across the dose steps, the Mounjaro pricing overview explains what to expect at each stage of treatment.

How do clicks relate to the dose chart?

The Mounjaro KwikPen is a click-dialled device. Each dose within a pen is set by turning the dial to the correct number of clicks, so understanding the click count for your prescribed dose matters practically. The 2.5 mg dose uses a specific click count, as does each subsequent strength, and the number of clicks is not simply proportional to the dose number in a way that's intuitive at first glance.

This is where the Mounjaro dose chart with clicks page is worth bookmarking: it maps each of the six doses to its corresponding click setting, reducing the risk of dial error. A related resource covers the click settings specific to the 5 mg pen for anyone currently at that step. Incorrect click settings are one of the most common practical questions after a dose change, and knowing the right number before you inject is part of safe use. Your Patient Information Leaflet is the definitive source, always cross-reference it. If there's any doubt, contact your prescriber before administering a dose.

Tirzepatide is also available under its generic name, and the tirzepatide dose chart covers the same schedule from a clinical rather than brand perspective, which can be useful if your correspondence from a prescriber uses the generic name.

What happens at the end of the dose chart, is 15 mg always the goal?

Reaching 15 mg is not the objective for everyone. For some people, 10 mg or 12.5 mg delivers sustained, well-tolerated weight loss without the additional gastrointestinal burden that a further step might bring. NICE's appraisal of tirzepatide (TA1026) notes that if less than 5% weight loss is achieved after six months at the highest tolerated dose, the clinical picture should be reviewed. That review is a conversation with your prescriber, not an automatic next step.

The idea of a personal maintenance level, sometimes called a maintenance plan, recognises that the highest dose is not always the best dose. What matters is the dose that produces meaningful progress with side effects you can manage long term. The Mounjaro maintenance plan page covers what longer-term treatment looks like once you've settled at your optimal dose. If you're still exploring whether Mounjaro is the right treatment for you, the weight-loss treatments overview lays out how it fits alongside other licensed options.

These are prescription-only medicines. The dose chart describes the framework; a GPhC-registered prescriber applies it to your individual health picture. If you'd like that assessment, you can start your free consultation with our clinical team today.